Abstract Coronary microvascular dysfunction (CMD) can result from structural and functional abnormalities at the intramural and small coronary vessel level affecting coronary blood flow autoregulation and consequently leading to impaired coronary flow reserve. CMD often co-exists with epicardial coronary artery disease but is also commonly seen in patients with various forms of heart disease, including dilated, hypertrophic, and infiltrative cardiomyopathies. CMD can go unnoticed without any symptoms, or manifest as angina, and/ or dyspnea, and contribute to the development of heart failure, and even sudden death especially when co-existing with myocardial fibrosis. However, whether CMD in non-ischemic cardiomyopathy is a cause or an effect of the underlying cardiomyopathic process, or whether it can be potentially modifiable with specific therapies, remains incompletely understood.
Introduction
Increased availability of positron emission tomography (PET) scanners, PET perfusion tracers, and advanced software tools has fueled an exponential growth in cardiac PET. Extensive literature supports the powerful role of perfusion defects and left ventricular ejection fraction (LVEF) on PET myocardial perfusion imaging (MPI) to accurately diagnose obstructive coronary artery disease (CAD) and to stratify risk. Peak hyperemic myocardial blood flow (MBF) and coronary flow reserve (CFR, stress/rest MBF) quantified by PET provide insights into coronary microvascular function. Coronary microvascular dysfunction (CMD) is an integral feature of ischemic and several of the non-ischemic cardiomyopathies. In this paper, we critically review the literature on the utility of cardiac PET in the evaluation of CMD in individuals with nonischemic cardiomyopathy.
Role of PET in the evaluation of CMD
The coronary microvasculature, the small vessels that perfuse the myocardium, is comprised of the coronary prearterioles (<500 μm) and arterioles (<100 μm). These microvessels are dynamic and metabolically responsive with alterations in vascular tone matching myocardial oxygen needs [1] . Release of H 2 O 2 through diseased coronary arteries has been implicated in a proinflammatory environment potentiating myocardial fibrosis and hypertrophy ( Fig. 1) , which may be pathophysiologically relevant in non-ischemic cardiomyopathies [1] .
Dysfunction of the coronary microvasculature can result from a variety of structural or functional alterations with downstream effects, and irrespective of underlying etiology, will impair hyperemic MBF. Imaging of microvascular structural alterations is currently challenging, due to the limits of spatial resolution of the imaging techniques. However, hyperemic MBF can be accurately imaged using invasive or noninvasive techniques and has emerged as one of the robust metrics for CMD. Noninvasively measured MBF at rest, during maximal hyperemia, and coronary vasodilatory capacity estimated by CFR (ratio of peak hyperemic MBF to rest MBF) are increasingly being used in clinical practice. Presently, MBF can be quantified noninvasively using radionuclide imaging, cardiac magnetic resonance (CMR), or contrast echocardiography, but PET is the mostly commonly used and validated technique. With the most modern PET scanners, MBF can be obtained during routine PET MPI acquisition with O-15 water, N-13 ammonia, or Rubidium-82. MBF by each of these tracers has been well validated by microsphere studies in animals and found to be highly reproducible. Several easy-to-use software programs are commercially available to quantify MBF and CFR. MBF and CFR quantified by PET is, thus, the technique with the greatest wealth of evidence and the most widely used method for evaluation of CMD.
CMD in non-ischemic cardiomyopathies
Coronary microvascular dysfunction can coexist with several cardiovascular diseases. Camici and colleagues have classified CMD into four types depending on the presence or absence of epicardial CAD and myocardial diseases: Type 1, no myocardial disease or CAD, Type 2, myocardial disease without CAD, Type 3, CAD, and type 4, iatrogenic [2, 3] . In this review, we focus on Type 2 CMD-myocardial disease without CAD i.e., non-ischemic cardiomyopathy associated with dilated cardiomyopathy, hypertrophic cardiomyopathy, and infiltrative cardiomyopathy (Fabry's disease or amyloidosis). CMD is frequent in individuals with non-ischemic cardiomyopathy (Table 1) . It may cause minimal symptoms in some patients or manifest as chest pain, dyspnea, and/or ischemic electrocardiographic changes in the absence of obstructive epicardial CAD. Whether CMD in non-ischemic cardiomyopathy is a cause or an effect of the underlying cardiomyopathic process is not known, but CMD has been associated with worsening systolic and diastolic function, worsening heart failure, sudden death, and poor clinical outcomes. Importantly, CMD is potentially modifiable with some of the heart failure therapies.
Dilated cardiomyopathy
Dilated cardiomyopathy is myocardial dysfunction in the absence of CAD. CMD in dilated cardiomyopathy portends worse prognosis (Table 1) . Dilated myocardial phenotype and a multitude of myocardial histological changes may be responsible for CMD in dilated cardiomyopathy. The volume fraction of myofibrils is reduced [4] , and myocardial fibrosis is increased [4] , when compared to ischemic cardiomyopathy [5] , or control hearts [6] . Myocardial capillary density is decreased significantly [5, 6] , but without prominent changes in the arterioles.
Peak vasodilator hyperemic MBF and CFR are reduced in individuals with dilated cardiomyopathy (Table 1, Fig. 2 ) even prior to onset of symptomatic heart failure (1.91 ± 0.76 ml/g/ min) when compared to healthy subjects (3.78 ± 0.86 ml/g/ min) [7] . CMD is partly mediated by high resting sympathetic tone, with reduced coronary vascular resistance at rest and blunted flow response to cold stress [8] . Regional flow heterogeneity with relatively reduced perfusion to the septum in relation to the lateral wall, as well as regional metabolic and contraction changes, are observed in individuals with LBBB [9, 10] , but these changes appear to be independent of perfusion or CMD [11] . Neglia et al. [7] showed that reduced peak hyperemic MBF of <1.36 ml/g/min is an independent predictor of death (relative risk 3.5) and development or progression of heart failure in individuals with dilated cardiomyopathy. Similarly, Majmudar et al. [12] showed that a composite event of cardiac death, heart failure hospitalization, aborted sudden death, or late revascularization was twofold higher in individuals with non-ischemic cardiomyopathy and CFR ≤ 1.65 compared to CFR > 1.65.
Investigators have evaluated the modifiability of CMD in dilated cardiomyopathy using a variety of heart failure therapies. Angiotensin converting enzyme inhibitors, widely used in the management of heart failure, appear to improve CMD via a NO and a bradykinin-mediated mechanism in an animal model of tachycardia-mediated cardiomyopathy [13] . Similarly, in a prospective randomized placebo controlled study of 16 subjects, peak hyperemic MBF improved 6 months after carvedilol therapy (1.67 ± 0.63 to 2.58 ± 1.04, p < 0.001) compared to placebo (1.80 ± 0.84 to 1.77 ± 0.60, NS) [14] . Cardiac resynchronization therapy is also promising to improve LVEF fraction in dilated cardiomyopathy; in one study, wall stress, peak hyperemic MBF, and CFR improved along with LVEF and wall stress [15] . However, establishing a direct link between improvement in CMD from the various advanced heart failure therapies and survival benefit may be difficult to establish.
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is a sarcomeric disease characterized by a hypertrophic myocardial phenotype. Symptoms of chest pain, heart failure, and sudden death in HCM have been attributed to CMD. CMD with associated myocyte ischemia has been postulated as common mechanism underlying arrhythmias and sudden death in hypertrophic cardiomyopathy [16] . Although the predominant mechanism responsible for CMD in hypertrophic cardiomyopathy is felt to be structural remodeling of the arterioles and myocardial fibrosis; other mechanism such as increased LV mass [17] , capillary rarefaction [18] , extrinsic compressive forces [17] , compression of the septal perforator arteries, myocyte disarray, and spasm have also been implicated [18] . The intramural vessel Echocardiography showed a severely dilated left ventricle with severely reduced systolic function. Cardiac PET showed no definite evidence of vasodilatorinduced myocardial ischemia. However, global peak hyperemic myocardial blood blow was moderate to severely reduced, and coronary flow reserve was mildly impaired. Invasive coronary angiography demonstrated normal epicardial coronary arteries. Overall, findings were consistent with a form of non-ischemic dilated cardiomyopathy with associated coronary microvascular dysfunction walls are hypertrophied due to proliferation of smooth muscles and collagen in the media (and intima) causing luminal narrowing [18, 19] .
Interestingly, coronary microvascular function is not impaired in carriers of hypertrophic cardiomyopathy mutations, despite early evidence of impaired energetics [20] , but is often abnormal in hypertrophic cardiomyopathy patients (Fig. 3) , even with mild or no symptoms. Compared to controls, peak hyperemic MBF (1.50 ± 0.69 vs. 2.71 ± 0.94 ml/min/g, P < 0.001) and CFR (1.80 ± 0.70 vs. 2.70 ± 0.90, P < 0.001) are substantially reduced in hypertrophic cardiomyopathy (Table 1) . However, CMD is not invariably present in all patients with HCM. Previous studies have demonstrated that patients with HCM have a wide range of CFR at diagnosis, where some patients present with normal CFR (implying relatively preserved or just minimally impaired coronary microvascular function) and others with severely reduced CFR (consistent with significant CMD) [21] .
The reasons for this heterogeneity of CFR in HCM are not completely understood but appear to be multifactorial. Firstly, a pre-determined or inherited component is likely to play a role. This was suggested by Olivotto et al. [22] , in a study where the investigators observed significantly lower peak MBF (1.7 ± 0.6 vs. 2.4 ± 1.2 ml/min/g; P < 0.02) by PET as well as higher prevalence of myocardial late gadolinium enhancement (LGE, 96 vs. 67%, P = 0.038) by CMR in patients testing positive for myofilament-encoding genes compared to genotypenegative HCM patients despite similar baseline characteristics, including maximal LV wall thickness, between Fig. 3 Rest-Regadenoson N-13 ammonia PET/CT in a patient with hypertrophic cardiomyopathy. A 22-year-old man with known hypertrophic cardiomyopathy without LVOT obstruction and ongoing chest discomfort was referred for rest and regadenoson N-13 ammonia PET/CT for evaluation of coronary microvascular dysfunction. Stress and rest images are shown in alternate rows with short axis images (top two rows) from apex to base (left to right), horizontal long axis images (middle two rows) from the inferior to the anterior wall (left to right), and vertical long axis images (bottom two rows) from the septum to the lateral wall (left to right). On the right bottom panel, stress, rest, and reversibility polar plots (top row) and summed stress, summed rest, and summed difference scores are shown (bottom panel). LVEF declined from 56% at rest to 39% after vasodilator stress. Peak hyperemic myocardial blood flow and coronary flow reserve were substantially reduced for age. Coronary CT angiography shows normal epicardial coronary arteries with prominent myocardial crypts in the mid portion of the anterior wall groups [22] . This study suggested a genetic predisposition for the development of CMD in HCM.
The degree of LV hypertrophy is also an important predictor of CMD. Several authors have observed an inverse correlation between stress-MBF (and thus CFR) measured by PET or CMR and maximal LV wall thickness in HCM [17, 21, 23] , myocardial mass indexed to body surface area [17] , and serum NT pro BNP (a marker of increased myocardial wall stress) [17] . Ex vivo studies have provided additional morphologic and histophatologic correlations in this respect [18, 24, 25] . Tanaka et al. observed that the percentage of luminal narrowing of intramural coronary vessels was inversely correlated with heart weight and myocyte size in the LV septum and free wall during necropsies of individuals with HCM [18] , and Krams et al. described an inverse relationship between normalized coronary arteriolar lumen and degree of LV hypertrophy in myectomy specimens of HCM patients [25] . Nevertheless, while CMD is clearly more pronounced in myocardial segments with hypertrophy [23] , segments without hypertrophy also demonstrate CMD [26] implicating mechanisms beyond myocardial hypertrophy.
Arteriolar remodeling is most prominent in regions with fibrosis suggesting a possible causal role leading to fibrosis [18] ; intramural arteriolar remodeling in myocardial samples from infarcts support this being a developmental abnormality. In fact, impaired CFR and myocardial ischemia are also significantly more prevalent in the presence of myocardial LGE on CMR (Fig. 4) , a marker of myocardial fibrosis in HCM [23, 27, 28] . In the absence of LGE, patients with HCM usually exhibit normal to low-normal CFR, whereas in the presence of LGE, CFR varies widely with approximately 50% of symptomatic patients demonstrating reduced CFR (<2.0) in some series [28] . Postmortem studies have yielded similar findings [18, 19] . Baron et al. evaluated 48 necropsies of patients with HCM and observed a significantly higher frequency of small vessel disease changes in myocardium tissue sections that exhibited moderate or severe fibrosis (74%) compared to sections with mild or no fibrosis (30%) [19] . Subendocardial perfusion is particularly impaired suggesting a role for extravascular compressive forces in addition to reduced capillary density [17, 23] . Although LV outflow tract gradient may increase myocardial wall stress and is independently associated with worse clinical outcomes [29] , a gradient at rest or provoked by amyl nitrate, is not an independent predictor of peak hyperemic MBF [17, 21, 29] . In conjunction, these data highlight the close inter-relation that exists between CMD, genetic-predisposition, LV hypertrophy, and fibrosis in HCM.
Finally, CMD in individuals with hypertrophic cardiomyopathy signals future risk of LV systolic dysfunction, [30] with a peak hyperemic MBF < 1.11 ml/g/min portending a 7.5-fold risk of developing LVEF <50%, or remodeling. These individuals also carry a poor prognosis with a 20-fold increased relative risk (95% CI, 2.4 to 167.8; P = 0.003) of poor clinical outcomes (composite end-point of death, Fig. 4 Cardiac magnetic resonance and rest-regadenoson N-13 ammonia PET/CT in a patient with apical-variant hypertrophic cardiomyopathy. Patient is a 40-year-old male who presented with significant exertional chest pain and functional class III. He had angiographically normal epicardial coronary arteries. However, cardiac magnetic resonance (CMR) imaging revealed classic appearance of apical-variant hypertrophic cardiomyopathy with significant late gadolinium enhancement (LGE) mostly confined to the hypertrophic apex. On further evaluation, N-13 ammonia PET showed evidence of significant vasodilator-induced ischemia and coronary microvascular dysfunction particularly at the apex progressive heart failure to NYHA class 3 or 4, and ventricular tachyarrhythmias necessitating ICD [29] .
Fabry's disease
Anderson Fabry's disease is an X-linked lysosomal storage disease that is caused by a loss of function mutation in the GLA gene that encodes for alpha galactosidase A. It is characterized by deposition of glycosphingolipid in the heart, skin, kidneys, and nerves causing organ dysfunction and premature mortality [31] . A seminal cardiac pathology in Fabry's cardiomyopathy is globotria osylceramide deposition in myocytes with vacuolization [32] . These deposits may activate a variety of signaling pathways leading to hypertrophy, apoptosis, necrosis and fibrosis, which increase coronary vascular resistance, myocardial oxygen demand, and cause CMD [33] . CMD has the potential to cause myocardial fibrosis in Fabry's disease [34] . Although CMD is more severe among those with LV hypertrophy, it is also seen in women and among individuals without LV hypertrophy [33] ; these authors, thus, propose that in addition to capillary rarefaction, and microvascular compression, pathologies related to LV hypertrophy, endothelial dysfunction from the storage of glycosphingolipids, dysregulation of the nitric oxide pathway, and microvascular remodeling may contribute to CMD in Fabry's disease [33] . Also, on intravascular ultrasound imaging patients with Fabry's disease demonstrate diffuse hypoechoic coronary plaques with greater lipid cores compared to control individuals [35] .
CMD is prevalent in Fabry's disease, with angina or chest pain reported in about 19% of men and women (not on therapy) and in 24-30% of women and men on enzyme replacement therapy [36] . Myocardial perfusion reserve was significantly lower in Fabry's disease patients compared to control patients (dipyridamole O-15 water PET, CFR 3.3 ± 1.2 vs. 4.5 ± 3.6, p = 0.02 [37] ; and adenosine O-15 water PET, CFR 1.41 ± 0.39 vs. 3.03 ± 0.85, p < 0.0001 [38] ). But, with enzyme replacement therapy, despite significant reduction in plasma concentrations of globotriaosylceramide, CFR did not improve in one study after approximately 10 months of therapy [38] and failed to improve in another study at 6 months and 12 months post-therapy [39] . Similarly, systolic, and diastolic parameters evaluated by CMR and echocardiography did not change even ammonia PET/CT was performed at baseline (a) and follow-up images 6 months after completion of chemotherapy (b). Perfusion images are displayed as described in Fig. 3 . Peak hyperemic myocardial blood flow and coronary flow reserve were substantially reduced at baseline and improved significantly on follow-up (although still abnormal) after 24 months of therapy [40] . These studies suggest that other mechanisms may be involved in cardiac manifestations of Fabry's disease.
Amyloidosis
Cardiac amyloidosis is part of a systemic protein misfolding disorder resulting in deposits of amyloid fibrils (misfolded proteins) in the myocardial interstitum and in the perivascular spaces. Cardiac amyloidosis can be broadly classified into light chain amyloidosis (AL, a plasma cell dyscrasia) and transthyretin amyloidosis (ATTR). ATTR amyloidosis is of two types: ATTRwt, a wild type disease of aging or ATTRmt, a familial autosomal dominant disease resulting from a mutation of the TTR gene. Cardiac involvement is common in AL disease and ubiquitous in ATTR disease and is the most likely cause of heart failure and death in these patients. Myocardial dysfunction in amyloidosis is mediated via at least two mechanisms: (1) amyloid deposits and (2) circulating light chain related toxicity in individuals with AL [41] .
Angina without epicardial CAD has been well-described in individuals with amyloidosis [42] . Perivascular amyloid deposits [43] , intracoronary amyloid deposits [44] , interstitial amyloid deposits with increased LV mass [43] , restrictive heart failure and high LV filling pressures, autonomic neuropathy, and endothelial dysfunction may account for CMD in amyloidosis [43] . Interstitial and perivascular amyloid deposits may compress coronary microvessels thereby increasing coronary microvascular resistance. Increased LV mass may reduce capillary density and decrease diastolic perfusion from high LV filling pressures. Autonomic dysfunction, a well-known manifestation of amyloidosis, may also result in vasomotor dysfunction [41] .
From a symptom perspective, angina pectoris can be the first manifestation of cardiac amyloidosis. This became evident in a study of Suwaida et al. [42] , in which they investigated 153 patients with chest pain and angiographically normal coronary arteries and performed invasive CFR assessment using Doppler flow wires, and infusions of intracoronary adenosine and acetyl choline to test microvascular and endothelial dysfunction respectively. CFR was calculated as the ratio of hyperemic to basal average peak velocity of the distal vessel. Of the 153 patients studies, five individuals (CFR range, 1.6 to 2.3) were subsequently diagnosed with systemic AL amyloidosis (9-48 months later), suggesting that coronary microvascular dysfunction may precede overt cardiac amyloidosis by several months to years. In another study, brachial artery flowmediated dilation was substantially reduced in individuals with AL cardiac amyloidosis [45] . The results of these two studies are supported by ex vivo studies demonstrating that exposure to AL proteins impaired smooth muscle relaxation in human arterioles from atrial and adipose tissue [46] , and thus laid the foundation for the possibility of ALmediated CMD.
In a prospective study, cardiac structure on echocardiography and coronary microvascular function (rest and vasodilator stress N-13 ammonia) was prospectively evaluated in 21 individuals with cardiac amyloidosis (15 AL, 6 ATTR) without epicardial CAD [47] . Minimal coronary vascular resistance was markedly increased (111 ± 40 vs. 70 ± 19 ml/g/min/ mmHg; P < 0.004) and stress MBF (0.85 ± 0.29 vs. 1.85 ± 0.45 ml/g/min, P < 0.0001) and CFR (1.19 ± 0.38 vs. 2.23 ± 0.88, P < 0.0001) were substantially reduced in subjects with amyloidosis compared to subjects with hypertensive LV hypertrophy. Minimal coronary vascular resistance and CFR were linearly related to parameters of diastolic dysfunction (e', r = 0.41, P = 0.002; e', r = 0.49, P = 0.008, respectively), and subclinical systolic dysfunction (longitudinal strain, r = 0.48, P = 0.01; r = −0.44, P = 0.03, respectively). CMD from amyloid deposits may potentially explain a greater vulnerability of these individuals to ischemia and subclinical impairment of LV systolic function. Notably, MBF and CFR improved remarkably in two individuals with active AL-CMP and hematological and clinical response at 6 months, despite no change in LV wall thickness, implying reversibility of CMD and supporting a role for light chain toxicity in CMD (Fig. 5 ).
Conclusions
Individuals with non-ischemic cardiomyopathies manifest varying degrees of CMD, with a greater magnitude of CMD in hypertrophic heart diseases compared to dilated cardiomyopathy. CMD may be the result of the underlying cardiomyopathic process but in turn may potentiate myocardial fibrosis and dysfunction. Myocardial ischemia from CMD may predispose some of these individuals to the occurrence of sudden cardiac death. Strategies that improve CMD may be important modifiable targets for therapy to improve outcomes in individuals with non-ischemic cardiomyopathies.
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